All In MedTech

FDA Clearance Tracker · K213652

Cresilon Hemostatic Gel, CHG, Cresilon Hemostatic Gel (CHG)

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 19, 2026Latest source record: Jun 28, 2023 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Jun 28, 2023

Substantially Equivalent

Time to decision

586 days

Received Nov 19, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Unclassified

The decision

FDA number
K213652
Device name
Cresilon Hemostatic Gel, CHG, Cresilon Hemostatic Gel (CHG)
Applicant location
Brooklyn, NY
Received
Nov 19, 2021
Decided
Jun 28, 2023
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Unclassified

Every decision under product code QSY

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code QSY. The earliest in FDA's data is K893123, decided Feb 13, 1990.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Cresilon, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.